Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial

Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial

PURPOSE The addition of ovarian function suppression (OFS) for 5 years to tamoxifen (TAM) for treatment of premenopausal patients with breast cancer after completion of chemotherapy has beneficial effects on disease-free survival (DFS). This study evaluated the efficacy of adding 2 years of OFS to T...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology 2020-02, Vol.38 (5), p.434-443
Hauptverfasser: Kim, Hyun-Ah, Lee, Jong Won, Nam, Seok Jin, Park, Byeong-Woo, Im, Seock-Ah, Lee, Eun Sook, Jung, Yong Sik, Yoon, Jung Han, Kang, Sung Soo, Lee, Soo-Jung, Park, Kyong Hwa, Jeong, Joon, Cho, Se-Heon, Kim, Sung Yong, Kim, Lee Su, Moon, Byung-In, Lee, Min Hyuk, Kim, Tae Hyun, Park, Chanheun, Jung, Sung Hoo, Gwak, Geumhee, Kim, Jeryong, Kang, Sun Hee, Jin, Young Woo, Kim, Hee Jeong, Han, Se-Hwan, Han, Wonshik, Hur, Min Hee, Noh, Woo Chul
Format: Artikel
Sprache:eng
Schlagworte:
Life Sciences & Biomedicine
Oncology
Science & Technology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:PURPOSE The addition of ovarian function suppression (OFS) for 5 years to tamoxifen (TAM) for treatment of premenopausal patients with breast cancer after completion of chemotherapy has beneficial effects on disease-free survival (DFS). This study evaluated the efficacy of adding 2 years of OFS to TAM in patients with hormone receptor-positive breast cancer who remain in a premenopausal state or resume ovarian function after chemotherapy. PATIENTS AND METHODS We enrolled 1,483 premenopausal women (age
ISSN:0732-183X
1527-7755
DOI:10.1200/JCO.19.00126